Soluble CD163 is increased in patients with acute pancreatitis independent of disease severity

Karrasch, Thomas; Brünnler, T.; Hamer, Okka W.; Schmid, Kurt; Voelk, Markus; Herfarth, Hans H; Buechler, Christa

doi:10.1016/j.yexmp.2015.07.006

Cited by 9 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Soluble CD163 (sCD163) is generated by proteolytic cleavage of membrane protein and then shed into serum or tissue fluid as a soluble form ( 13 ). Some papers have been reported that serum sCD163 is increased in the inflammatory and critical diseases ( 9 , 14 ). Strikingly, serum sCD163 is highly expressed in several malignancies, including liver cancer, ovarian cancer, leukemia and multiple myeloma, and sCD163 is identified as negative prognostic factors for these cancers ( 15 – 18 ).…”

Section: Introductionmentioning

confidence: 99%

Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer

et al. 2017

View full text Add to dashboard Cite

Soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163) are macrophage activation markers which have previously been demonstrated to be increased in patients with inflammation, auto-immunity and malignancies. To investigate the clinical diagnostic and prognostic significance of preoperative serum sMR and sCD163, the present study investigated 143 gastric cancer (GC) patients, 66 subjects with benign gastric disease and 59 healthy controls, using an ELISA assay. Preoperative serum levels of sMR and sCD163 ranged from 0.165 to 0.885 µg/ml (median=0.374 µg/ml) and from 0.291 to 1.760 µg/ml (median=0.628 µg/ml) in GC patients, respectively. The expression levels of sMR and sCD163 were elevated compared with all controls (P<0.0001). Receiver operating characteristic analyses suggested that the optimum diagnostic cut-offs for sMR and sCD163 were 0.3405 µg/ml [area under curve (AUC) 0.7284, sensitivity 61.54%, and specificity 73.60%] and 0.6645 µg/ml (AUC 0.7766, sensitivity 53.85%, and specificity 86.40%), respectively. Notably, the measurement of serum sMR and sCD163 levels in conjugation, markedly enhanced the diagnostic accuracy (AUC 0.8490, sensitivity 70.63% and specificity 84.00%). Preoperative serum sMR and sCD163 levels correlated significantly with serum carcinoembryonic antigen, CA199, CA724 and CA125 concentrations in GC patients (P<0.05), however this association was not observed with sMR and CA724. High preoperative serum sMR and sCD163 levels correlated significantly with shorter overall survival (P=0.0041; P<0.0001, respectively) and were demonstrated to act as adverse prognostic factors (P=0.006; P<0.001, respectively). Furthermore, preoperative serum sMR and sCD163 levels correlated positively with the degree of lymphatic and distant metastasis of GC. In conclusion, preoperative serum sMR and sCD163 may be novel diagnostic and prognostic markers for GC and further studies are required in order to elucidate the underlying molecular mechanisms of sMR and CD163 in the development and progression of GC.

show abstract

Section: Introductionmentioning

confidence: 99%

Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, Cheng et al (2017) pointed that CD163 and STAT3 are co-upregulated in gastric cancer and CD163 is a novel downstream target gene of STAT3 [7]. Upregulation of CD163 was detected in atherosclerosis, diabetes, acute pancreatitis, and cancer [27,10,24], and it was found that CD163 is signi cantly increase in the peripheral blood of ischemic stroke patients [21].…”

Section: Discussionmentioning

confidence: 99%

STAT3-CD163 crosstalk exhibits promising biomarkers for a progressive Ischemic cardiomyopathy; integrative computational and gene expression profiling based on GEO datasets

Mohareb¹,

Kariem²,

Tohamy³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background:Ischemic heart diseaseis one of the heaviest health-related burdens worldwide.We aimed to identify the common hub mRNA and pathways that are involved in pathological progression of ischemic cardiomyopathy(ICM). Methods:To explore potential differentially expressed genes (DEGs) of all ischemic heart disease stages, we used chipster and GEO2R tools to analyze of retrieved eight high throughput RNA datasets obtained from GEO database. Gene Ontology functional annotation and Pathways enrichment analyses were used to obtain the common functional enriched DEGs which were visualized in protein–protein interactions (PPI) network to explore the hub mRNA according to the interaction scores. Validation qRT-PCR was carried out for blood and cardiac biopsies compared with controls to validate the determined four hub mRNAs and subsequently reviewed inside comprehensive published meta-analysis database. The validated mRNAs were visualized in two interaction modules. Finally screening of approved drugs was applied. Results: 15 common DEGs with p value ≤ 0.01 were identified and carbohydrate &amino acids metabolism and inflammatory responses were significantly enriched. STAT3, CEBPD, GLUL and CD163 were hub enriched mRNAs with interaction score ≥ 0.50. Our qRT-PCR analysis showed increased expression of STAT3 over all patients groups and CD163 mainly in cardiac samples with remarked ascending manner. Interaction modules showed co-regulators supporting high STAT3-CD163 connectivity providing potential role of STAT3-CD163 crosstalk mediated inflammatory responses in ICM progression. We determined two reported drugs targeting STAT3. Conclusion:Post analysis of the used GEO datasets and qRT-PCR data pointed that STAT3-CD163 crosstalk was potential biomarkers for ICM progression. Clinical trial registration: www.clinicaltrials.gov, Identifier: NCT05508269

show abstract

“…It is, nevertheless, recognized that sCD163 levels correlate with fibrosis stage, the NAFLD activity score, and hepatic inflammation observed in other liver diseases [32 , 37 , 40] . sCD163 is a marker of acute pancreatitis [41] and a predictor of type 2 diabetes risk [42] , but an association with pancreatic fat has not been reported. Given the close relationship between pancreatic fat and abdominal fat depots, further studies are needed to corroborate this finding.…”

Section: Discussionmentioning

confidence: 99%

Links between ectopic and abdominal fat and systemic inflammation: New insights from the SHIP-Trend study

Ponce-de-Leon

Hannemann

Linseisen

et al. 2022

Digestive and Liver Disease

View full text Add to dashboard Cite

Soluble CD163 is increased in patients with acute pancreatitis independent of disease severity

Cited by 9 publications

References 30 publications

Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer

Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer

STAT3-CD163 crosstalk exhibits promising biomarkers for a progressive Ischemic cardiomyopathy; integrative computational and gene expression profiling based on GEO datasets

Links between ectopic and abdominal fat and systemic inflammation: New insights from the SHIP-Trend study

Contact Info

Product

Resources

About